CellCept (Mycophenolate Mofetil Oral Suspension) and Rifadin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Ask your doctor before using mycophenolate mofetil together with rifAMPin. Using these medications together may decrease the effects of mycophenolate mofetil. Given the risk of organ rejection associated with inadequate mycophenolate mofetil blood levels, mycophenolate mofetil should not be administered with rifAMPin unless the potential benefit outweighs the risk. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with rifampin may decrease the plasma concentrations of mycophenolic acid (MPA). The mechanism is thought to involve induction of MPA glucuronidation via gastrointestinal and hepatic uridine diphosphate glucuronosyltransferase (UGT) isozymes and reduction of enterohepatic recirculation of MPA metabolites secondary to competitive inhibition of multidrug resistance-associated protein 2 (MRP2)-mediated biliary excretion by rifampin. In one case report, a 67% decrease in dose-corrected MPA systemic exposure (AUC) was reported in a heart-lung transplant patient during concomitant treatment with mycophenolate mofetil and rifampin. Two weeks after discontinuation of rifampin therapy, the dose-corrected AUC of MPA increased by 221% and the 12-hour trough plasma concentration increased by approximately 7-fold. Another study in pediatric liver transplant patients also reported suboptimal levels of MPA in 2 patients who received concomitant treatment with rifampin, despite a 2-fold increase in the mycophenolate mofetil dosage. In a study with 8 kidney transplant recipients, coadministration of mycophenolate mofetil 750 mg to 1 g twice daily and rifampin 600 mg daily for 8 days decreased MPA systemic exposure (AUC) and trough plasma concentration by an average of 17.5% and 48.8%, respectively. In addition, the AUCs of the primary metabolites, MPA 7-O-glucuronide and MPA acyl-glucuronide, significantly increased by an average of 34.4% and 193%, respectively. Because MPA acyl-glucuronide is pharmacologically active and possesses proinflammatory properties, increased exposure may increase side effects such as diarrhea and anemia.

MANAGEMENT: Given the risk of organ rejection associated with inadequate immunosuppressant blood levels, mycophenolate mofetil and mycophenolic acid should not be administered with rifampin unless the potential benefit outweighs the risk.

CellCept (Mycophenolate Mofetil Oral Suspension)

Generic Name: mycophenolate mofetil

Brand name: Cellcept, Myfortic, MMF

Synonyms: CellCept

What is CellCept (Mycophenolate Mofetil Oral Suspension)?

Rifadin

Generic Name: rifampin

Brand name: Rifadin, Rifadin IV, Rimactane

Synonyms: n.a.

What is Rifadin?